Human medicines European public assessment report (EPAR): Qalsody, Tofersen, Date of authorisation: 29/05/2024, Revision: 1, Status: Authorised

New Fee Regulation working arrangements

Human medicines European public assessment report (EPAR): Duloxetine Lilly, duloxetine, Date of authorisation: 08/12/2014, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Cymbalta, duloxetine, Date of authorisation: 17/12/2004, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Yentreve, duloxetine, Date of authorisation: 11/08/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Date of authorisation: 01/10/2008, Revision: 18, Status: Authorised

Member states contact points for review of national versions of the content of mobile scanning and other technologies

Nitrosamine in vivo mutagenicity workshop, European Medicines Agency, Amsterdam, the Netherlands, from 11 July 2024, 12:00 (CEST) to 12 July 2024, 15:00 (CEST)

Minutes of the PRAC meeting 13-16 May 2024

List of medicines currently in PRIME scheme